BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• BioCapital

  Calibrant Biosystems Announces Gemini(TM) Drug Discovery and Development Presentations at 2008 American Association for Cancer Research Annual Meeting

  April 14, 2008

   · 

  1 min read
• Pharm Country

  Callisto Pharmaceuticals Receives Notice of Delisting From AMEX - Subject to Appeal

  April 14, 2008

   · 

  1 min read
• Drug Development

  Early Data on Amgen’s Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types

  April 14, 2008

   · 

  1 min read
• Drug Development

  Hollis-Eden Pharmaceuticals Inc. Presents Positive Data with APOPTONE(TM) in Preclinical Bone Model of Late-Stage Prostate Cancer

  April 14, 2008

   · 

  1 min read
• LifeCycle Pharma Summons Annual General Meeting

  April 14, 2008

   · 

  1 min read
• Drug Development

  New Data Continues to Support the Safety and Clinical Activity for Celsion Corporation’s ThermoDox(R) in Recurrent Breast Cancer

  April 14, 2008

   · 

  1 min read
• Business

  VioQuest Pharmaceuticals, Inc. Names Vernon L. Alvarez, Ph.D. as Vice President, Research & Development and Announces Resignation of Chief Scientific Officer

  April 14, 2008

   · 

  1 min read
• Frost & Sullivan Release: Need for Regulatory Compliance and Urgency to Improve Operational Efficiency to Push Growth of Automation and Control Solutions in the European Pharmaceutical Market

  April 14, 2008

   · 

  1 min read
• Drug Development

  Pharmacyclics, Inc. Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

  April 14, 2008

   · 

  4 min read
• Drug Development

  Isis Pharmaceuticals, Inc. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

  April 14, 2008

   · 

  7 min read